Minimal residual disease-based risk stratification in Chinese childhood acute lymphoblastic leukemia by flow cytometry and plasma DNA quantitative polymerase chain reaction

Autor:	Luk, CW, Lee, V, Leung, Y, Ng, MHL, Mejstrikova, E, Hrusak, O, Ling, SC, Li, CH, Lee, ACW, Cheuk, KLD, Ha, SY, Leung, AWK, Shing, MMK, Cheng, CK, Ip, RKL, Chan, NPH, Li, CK, Lau, KM, Cheng, SH
Jazyk:	angličtina
Rok vydání:	2013
Předmět:	Oncology Male Pathology Multivariate analysis Neoplasm Residual Oncogene Proteins Fusion lcsh:Medicine Pediatrics Polymerase Chain Reaction Hematologic Cancers and Related Disorders Molecular cell biology DNA amplification Recurrence hemic and lymphatic diseases Blood plasma Antineoplastic Combined Chemotherapy Protocols Longitudinal Studies Child lcsh:Science Multidisciplinary medicine.diagnostic_test Hematology DNA Neoplasm Precursor Cell Lymphoblastic Leukemia-Lymphoma Flow Cytometry Acute Lymphoblastic Leukemia Prognosis Nucleic acids medicine.anatomical_structure Real-time polymerase chain reaction Child Preschool Cohort Medicine Female Research Article Risk medicine.medical_specialty Adolescent Clinical Research Design Antineoplastic Agents Disease-Free Survival Flow cytometry Internal medicine Leukemias medicine Humans Pediatric Hematology Statistical Methods Immunoassays Childhood Acute Lymphoblastic Leukemia Biology business.industry lcsh:R Infant DNA Minimal residual disease body regions Pediatric Oncology Immunologic Techniques Clinical Immunology lcsh:Q Bone marrow business Cytometry
Zdroj:	PLoS ONE, Vol 8, Iss 7, p e69467 (2013) PLoS ONE
ISSN:	1932-6203
Popis:	Minimal residual disease, or MRD, is an important prognostic indicator in childhood acute lymphoblastic leukemia. In ALL-IC-BFM 2002 study, we employed a standardized method of flow cytometry MRD monitoring for multiple centers internationally using uniformed gating, and determined the relevant MRD-based risk stratification strategies in our local patient cohort. We also evaluated a novel method of PCR MRD quantitation using peripheral blood plasma. For the bone marrow flow MRD study, patients could be stratified into 3 risk groups according to MRD level using a single time-point at day-15 (Model I) (I-A: 10%), or using two time-points at day-15 and day-33 (Model II) (II-A: day-15
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02356b0cfb5c6ef3b26de06ecb3dd81d http://europepmc.org/articles/PMC3723913?pdf=render Zobrazit plný text záznamu Plný text ve formátu PDF